Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 – and without heart-related side-effects, according to a new study published by Henry Ford Health System.
In a large-scale retrospective analysis of 2,541 patients hospitalized between March 10 and May 2, 2020 across the system’s six hospitals, the study found 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine. None of the patients had documented serious heart abnormalities; however, patients were monitored for a heart condition routinely pointed to as a reason to avoid the drug as a treatment for COVID-19.
The study was published today in the International Journal of Infectious Diseases, the peer-reviewed, open-access online publication of the International Society of Infectious Diseases (ISID.org).
Patients treated with hydroxychloroquine at Henry Ford met specific protocol criteria as outlined by the hospital system’s Division of Infectious Diseases. The vast majority received the drug soon after admission; 82% within 24 hours and 91% within 48 hours of admission. All patients in the study were 18 or over with a median age of 64 years; 51% were men and 56% African American.
“The findings have been highly analyzed and peer-reviewed,” said Dr. Marcus Zervos, division head of Infectious Disease for Henry Ford Health System, who co-authored the study with Henry Ford epidemiologist Samia Arshad. “We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug. And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients.”
Read more at Henry Ford Health System
- South Africa reports additional almost 9,000 COVID-19 cases, Puts total over 200K
- Sweden Public Health Authority updated guidance concerning positive antibody test
- DRC Ebola outbreak #11: Cases and deaths rise, UN report on zoonotic diseases released
- Dengue: Laboratory-acquired case reported in North Carolina, according to study
- Philippines reports 2,000+ COVID-19 cases, Manila area hospitals reach full capacity
- Cambodia reports significant rise in measles
- Dallas County reports more than 1000 COVID-19 cases Sunday
- Tokyo COVID-19 cases rising, More than 100 cases for 5 consecutive days
This study has an age bias. The median age of the no drug group was 71. The median age of the hydroxychloroquine group was 53.
Who funded the study?
Is there a potential financial interest with the funder(s)
STATNEWS is saying there were methodological problems with the Henry Ford study.
https://www.statnews.com/2020/07/08/a-flawed-covid-19-study-gets-the-white-houses-attention-and-the-fda-may-pay-the-price/
Unfortunately the use of Hydroxychloroquine (with or without Azithromycin) as a treatment for COVID-19 has been highly politicized by the Media, the Medical Establishment, big Pharma and those with a political ideological bias. Therefore many doctors, medical centers, and patients have become unnecessarily confused and insecure about its use and probably at the cost of many tens of thousands of lives that could have been saved. Again as so often in the past, the quest for power and money stands in the way of humanity.